الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
Hepatitis C virus (HCV) infection is an outstanding cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC), with up to 185 million chronically infected subjects globally. HCV infection is a major health problem in Egypt as the country bears the uppermost incidence rate worldwide. Rapid progress was made in establishing effective therapy for HCV. For more than 20 years, therapy for HCV infection was based on boosting the immune response through the administration of Interferon-α (IFN-α).The limitations of IFN-α in both potency and adverse effects profile led to the emergence of all- oral, well-tolerated and highly effective direct acting antiviral agents (DAAs). Early studies described that DAAs monotherapy led to treatment failure and development of resistance, and these compounds were initially given together with pegylated IFN-α and Ribavirin (RBV), but subsequent approaches have successfully established the administration of multiple DAAs in combinations, with or without the addition of RBV.
The aim of this work was to study new- onset thrombocytopenia occurring in some patients receiving Sofosbuvir (SOF) and Daclatasvir (DAC) with or without RBV, and the possible mechanisms underlying this thrombocytopenia.